2-Trifluormethyl-4--chinolin | 18706-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-Trifluormethyl-4--chinolin
• 英文别名: pyridin-2-yl-(2-trifluoromethyl-quinolin-4-yl)-methanol；2-Pyridinyl[2-(trifluoromethyl)-4-quinolinyl]methanol；pyridin-2-yl-[2-(trifluoromethyl)quinolin-4-yl]methanol
• CAS: 18706-55-3
• 化学式: C₁₆H₁₁F₃N₂O
• 分子量: 304.271
• InChiKey: GKPZJLYZPJNJEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (II)
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1107761A2

  公开（公告）日：2001-06-20
• US6608085B1
  申请人：——

  公开号：US6608085B1

  公开（公告）日：2003-08-19
• [EN] 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS.(II)<br/>[FR] DERIVES DE 4-QUINOLINEMETHANOL UTILISES COMME ANTAGONISTES (II) DU RECEPTEUR DE PURINE
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000013682A2

  公开（公告）日：2000-03-16

  Wherein: R1 is hydrogen or alkyl; R2 is selected from hydrogen, alkyl, aryl and 4,5,6,7 or 8 membered satured and partially unsaturated heterocyclic rings containing one or more heteroatoms selected from O, S and N; R3 and R4 are independently selected from hydrogen, alkyl, aryl, COR13, CO2R13, CONR13R14, CONR13NR14R15, SO2R13, SO2NR13R14, SO2NR13NR14R15 or may form a ring. Or R1 and R4 together may form a heterocyclic ring or R2 and R3 together may form a heterocyclic ring. R5 and R6 are independently selected from hydrogen, alkyl, aryl and heterocyclic with the proviso that where R3 and R5 together form a ring, then R3, and R4 do not also form a ring; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, such as a movement disorder, for example, Parkinson's Disease or progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorder-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.